HC Wainwright & Co. Maintains Buy on Ekso Bionics Holdings, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Ekso Bionics Holdings but lowered the price target from $10 to $9.

October 29, 2024 | 10:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Ekso Bionics Holdings but lowered the price target from $10 to $9.
The analyst's decision to maintain a Buy rating suggests continued confidence in Ekso Bionics' potential, but the lowered price target indicates a more cautious outlook on its short-term valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100